Dr Lal Pathlabs' revenue growth was aided by a low base in Q3 while volume growth momentum continues. The street is a bit concerned about pricing pressure in an industry that has become so competitive now. In an interview to CNBC-TV18, Om Manchanda, CEO of Dr Lal Pathlabs discussed the company's Q3 performance.

Expect 26-27% margins for full year; Q3, Q4 to be good on low base: Dr Lal PathLabs

The company continues to remain highly competitive right across all segments of market ranging from preventive to illness and even to predictive going into the future, said Dilip Bidani, CFO, Dr. Lal PathLabs.

Acquisition in Bangladesh is minor, won't impact FY18 numbers: Dr Lal Pathlab

In an interview to CNBC-TV18, Doctor Om Manchanda, CEO of Dr Lal Pathlabs spoke about the results and his outlook for the company.

Volume performance to improve going ahead: Dr Lal PathLabs

High competitive pressures hamper volume growth this quarter. In an interview to CNBC-TV18, Dilip Bidani, CFO of Dr Lal PathLabs spoke about the results and his outlook for the company.

Dr Lal PathLabs to start Kolkata operations next year

Dr Lal Pathlabs' Kolkata labs will start operation by the second half of next year and company‘s central lab will come up by September 2017.

Dr Lal PathLabs sees margins declining 200-300 bps in 2-3 yrs

It has been a fairly good quarter on account of the seasonal fevers, said Dilip Bidani, CFO, Dr Lal PathLabs in an interview with CNBC-TV18.

Dr Lal PathLabs expects good volumes in Q2

The current spurt in diagnostic tests on dengue and chikungunya in areas like New Delhi will help Dr Lal PathLabs post good Q2 volumes, says Om Manchanda, Chief Executive of the healthcare firm.

Confident of beating sector growth of 16-17%: Dr Lal PathLabs

The quarter growth has been in-line with expectations, says Om Manchanda, CEO of Dr Lal PathLabs adding that some operational expenses will be seen in the next nine months.

Expect Dr Lal PathLabs to surpass industry growth in FY17: CEO

CEO Om Manchanda expects planned expansion of central lab network in Kolkata and Lucknow will help Dr Lal PathLabs to sustain margins in FY17. Diagnostics space which has low penetration in India makes it a good pitch for companies like Dr Lal PathLab, according to Citi's Prashant Nair.

May outperform industry's 17% FY17 growth rate forecast: Dr Lal

Dilip Bidani, CFO of Dr Lal PathLabs expects margins to dilute by 200-300 bps in coming two to three years, but says that growth will be better than the expected industry growth of 16-17 percent in FY17.

Expect margins to be in range of 25-26%: Dr Lal Pathlabs

Om Manchanda, CEO, Dr Lal Pathlabs, says the company's growth of 21 percent this quarter was in line with expectation and was mainly driven by volumes.